Raptor Pharmaceuticals Corp.
9 Commercial Boulevard
Suite 200
Novato,
CA 94949
United States - Map
Phone: 415-382-8111
Fax: 415-382-8002
Website: http://www.raptorpharma.com
Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. It engages in the research, manufacture, and commercialization of medicines to treat nephropathic cystinosis, non-alcoholic steatohepatitis (NASH), Huntington's disease (HD), and aldehyde dehydrogenase deficiency (ALDH2). Its lead compound includes RP103, a capsule containing enteric coated micro-beads of cysteamine bitartrate that has completed Phase 3 trial for the treatment of cystinosis, is in Phase 2/3 trial for treating HD, and is in Phase 2b trial for the treatment of NASH. The company clinical development pipeline comprises RP104, an enteric coated tablet formulation of cysteamine bitartrate that has completed Phase 2 trail; and Convivia, a Phase 2 product candidate for the management of acetaldehyde toxicity due to ALDH2 deficiency. Its preclinical product candidates include HepTide for the treatment of primary liver cancer and other liver diseases; NeuroTrans to deliver therapeutics across the blood-brain barrier; and WntTide for the treatment of breast cancer. Raptor Pharmaceuticals Corp. is headquartered in Novato, California. Key Statistics
| |
| Raptor Pharmaceuticals Corp.’s ISS Governance QuickScore as of Apr 1, 2013 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 9. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. Christopher M. Starr Ph.D.,
61
Co-Founder, Chief Exec. Officer, Director, Chief Exec. Officer of Raptor Pharmaceutical Inc and Director of Raptor Pharmaceutical Inc | 483.00K | 67.00K | Mr. Thomas E. Daley ,
50
Chief Bus. Officer | 345.00K | 0.00 | Dr. Patrice P. Rioux M.D., Ph.D.,
62
Chief Medical Officer and Chief Medical Officer of Raptor Therapeutics Inc | 416.00K | 136.00K | Ms. Kim R. Tsuchimoto CPA,
50
VP of Fin. | 334.00K | 32.00K | Mr. Marc P. Reichenberger ,
48
VP of Commercial Operations | 286.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.51(7.63%) 4:00PM EDT|After Hours
:
6.17